VERA insider buying and SEC filings, explained
Vera Therapeutics, Inc. · CIK 1831828
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$250K
Insiders who bought
1
Sold (not marked 10b5-1)
$1.9M
Planned sales (10b5-1)
$7.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 15, 2026 | Planned (10b5-1) | Marshall Fordyce (CEO and Director) sold 18,500 shares at $37.00 ($685K), marked as a 10b5-1 plan trade. Holdings down 7% to 235,244 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 2, 2026 | Planned (10b5-1) | Marshall Fordyce (CEO and Director) sold 18,500 shares at about $35.12 ($650K), marked as a 10b5-1 plan trade. Holdings down 7% to 235,244 shares. | SEC filing Filed Sep 4, 2026 |
| Jul 7, 2026 | Planned (10b5-1) Amended filing | Marshall Fordyce (CEO and Director) sold 46,250 shares at about $42.29 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 16% to 235,244 shares. This amends a filing from Jul 9. | SEC filing Filed Aug 12, 2026 |
| Jun 23, 2026 | Planned (10b5-1) Amended filing | Marshall Fordyce (CEO and Director) sold 18,500 shares at about $37.93 ($702K), marked as a 10b5-1 plan trade. Holdings down 7% to 235,244 shares. This amends a filing from Jun 24. | SEC filing Filed Aug 12, 2026 |
| May 12, 2026 | Planned (10b5-1) Amended filing | Marshall Fordyce (CEO and Director) sold 18,500 shares at about $36.74 ($680K), marked as a 10b5-1 plan trade. Holdings down 7% to 235,244 shares. This amends a filing from May 13. | SEC filing Filed Aug 12, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Marshall Fordyce (CEO and Director) sold 22,951 shares at about $44.05 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 9% to 235,244 shares. | SEC filing Filed Apr 15, 2026 |
| Feb 23, 2026 | Sale | Laurence Matthew Skelton (Chief Commercial Officer) sold 1,582 shares at about $41.98 ($66K). Holdings down 2% to 64,218 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | Robert Brenner (Chief Medical Officer) sold 2,151 shares at about $41.98 ($90K). Holdings down 4% to 50,947 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | Sean Grant (CFO) sold 4,949 shares at about $41.98 ($208K). Holdings down 4% to 114,181 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | Joseph R Young (SVP, Finance, Chief Acct Offcr) sold 3,117 shares at about $41.98 ($131K). Holdings down 5% to 64,722 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | Marshall Fordyce (CEO and Director) sold 16,925 shares at about $41.98 ($711K). Holdings down 6% to 257,163 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | William D. Turner (Chief Regulatory Officer) sold 2,187 shares at about $41.98 ($92K). Holdings down 5% to 45,313 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | David Lee Johnson (President / COO) sold 2,579 shares at about $41.98 ($108K). Holdings down 5% to 45,727 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Dec 15, 2025 | Planned (10b5-1) | William D. Turner (Chief Regulatory Officer) sold 10,000 shares at about $50.08 ($501K), marked as a 10b5-1 plan trade. Holdings down 31% to 22,500 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 11, 2025 | Purchase (code P) | Patrick G. Enright (Director) bought 5,882 shares at $42.50 ($250K), reported as a purchase (code P). New position of 5,882 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 15, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | William D. Turner (Chief Regulatory Officer) sold 10,000 shares at about $45.31 ($453K), marked as a 10b5-1 plan trade. Holdings down 31% to 22,500 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | William D. Turner (Chief Regulatory Officer) sold 10,000 shares at $40.00 ($400K), marked as a 10b5-1 plan trade. Holdings down 31% to 22,500 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 21, 2025 | Sale | Jason S Carter (Chief Legal Officer) sold 3,864 shares at about $27.82 ($107K). Holdings down 7% to 49,136 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 25, 2025 |
| Nov 11, 2025 | Sale | Joseph R Young (SVP, Finance, Chief Acct Offcr) sold 15,000 shares at about $29.06 ($436K). Holdings down 24% to 47,839 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
30 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow VERA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.